TrialMultiple sclerosis (Houndmills, Basingstoke, England)2024

A phase 2a open-label clinical trial to determine the effect of famciclovir on EBV activity as measured by EBV shedding in the saliva of patients with multiple sclerosis.

Ruth Dobson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.